At close: December 20 at 4:00:03 PM EST
After hours: 7:58:25 PM EST
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 2 | 4 | 4 |
| Avg. Estimate | -0.17 | -0.2 | -0.59 | -0.79 |
| Low Estimate | -0.18 | -0.21 | -0.6 | -0.89 |
| High Estimate | -0.16 | -0.19 | -0.58 | -0.68 |
| Year Ago EPS | -0.14 | -0.14 | -0.6 | -0.59 |
Revenue Estimate
| Currency in CAD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 3 | 4 | 4 |
| Avg. Estimate | -- | -- | -- | -- |
| Low Estimate | -- | -- | -- | -- |
| High Estimate | -- | -- | -- | -- |
| Year Ago Sales | -- | -- | -- | -- |
| Sales Growth (year/est) | 0.00% | 0.00% | 0.00% | 0.00% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.14 | -0.16 | -0.16 | -0.16 |
| EPS Actual | -0.14 | -0.14 | -0.13 | -0.15 |
| Difference | 0 | 0.02 | 0.03 | 0.01 |
| Surprise % | 0.00% | 10.64% | 17.02% | 3.23% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.17 | -0.2 | -0.59 | -0.79 |
| 7 Days Ago | -0.17 | -0.2 | -0.59 | -0.79 |
| 30 Days Ago | -0.17 | -0.2 | -0.59 | -0.79 |
| 60 Days Ago | -0.17 | -0.2 | -0.6 | -0.74 |
| 90 Days Ago | -0.18 | -0.2 | -0.62 | -0.76 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | 1 | 1 | 1 |
| Up Last 30 Days | 1 | 1 | 1 | 1 |
| Down Last 7 Days | 2 | 1 | 1 | 2 |
| Down Last 30 Days | 2 | 1 | 1 | 2 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| DMAC | -23.21% | -42.86% | 1.25% | -33.33% |
| S&P 500 | 5.00% | 12.00% | 2.10% | 12.20% |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/10/2024 |
| Initiated | HC Wainwright & Co.: Buy | 10/7/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 8/16/2024 |
| Maintains | Craig-Hallum: Buy to Buy | 3/21/2024 |
| Reiterates | Oppenheimer: Outperform to Outperform | 3/21/2024 |
Related Tickers
COCP Cocrystal Pharma, Inc.
2.2500
+7.14%
CHRO Channel Therapeutics Corporation
0.6435
-1.45%
ACHL Achilles Therapeutics plc
0.9811
-0.49%
TCRX TScan Therapeutics, Inc.
2.9700
+1.37%
IKT Inhibikase Therapeutics, Inc.
3.2000
+1.27%
PHIO Phio Pharmaceuticals Corp.
1.7600
+1.15%
CMPX Compass Therapeutics, Inc.
1.3800
+0.73%
PRLD Prelude Therapeutics Incorporated
1.3000
+46.40%
COEP Coeptis Therapeutics Holdings, Inc.
0.1415
-2.08%
JUNS Jupiter Neurosciences, Inc.
9.73
-10.41%